indications for treatment of Paget's disease
Last reviewed 01/2018
The following has been provided as potential indications for antiresorptive treatment in Paget's disease (1):
- pain in pagetic bone
- is the only symptom with firm evidence that therapy confers a clinical benefit
- it is important to differentiate bone pain resulting from pagetic activity (usually present at rest) which responds to antipagetic drugs from pain in a bone and/or joint deformity which occurs as a consequence of the disease (e.g. - osteoarthritic pain) which respond to analgesics, but not to antipagetic drugs (1)
- other indications in both symptomatic and asymptomatic patients with metabolically active PDB requiring therapy include
- those with involvement of long bones at risk of future bowing deformities
- those with extensive skull involvement at risk for future hearing loss
- those with pagetic changes in one or more vertebrae with the risk of various neurological complications
- those with PDB in bones adjacent to major joints with the risk of secondary arthritis
- complications caused by Paget's disease - treatment needs to be administered at an early stage of the disease (1)
- prior to orthopaedic surgery (2)
- hypercalcaemia resulting from immobilization (3).
Reference:
- (1) Michou L, Brown JP. Emerging strategies and therapies for treatment of Paget's disease of bone. Drug Des Devel Ther. 2011;5:225-39.
- (2) Langston AL, Ralston SH. Management of Paget's disease of bone. Rheumatology (Oxford). 2004;43(8):955-9.
- (3) Whyte MP. Clinical practice. Paget's disease of bone. N Engl J Med.2006;355(6):593-600.